Telescope Innovations

Telescope Innovations Receivables

The Accounts Receivable of Telescope Innovations (TELI.CN) as of Nov 5, 2026 is 411,000.00 CAD. In the previous year, Accounts Receivable was 1.58 M CAD — a change of -74.03% (lower).

Receivables

411,000.00CAD

YoY

-74.03%

Last updated:

Accounts Receivable of Telescope Innovations is 2025 411,000.00 CAD. Accounts Receivable of Telescope Innovations was 2024 1.58 M CAD. It decreases by -74.03% lower compared to the previous year.

The Telescope Innovations Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2020
0.00 CAD
Jan 1, 2021
63,700.00 CAD
Jan 1, 2022
719,100.00 CAD
Jan 1, 2023
473,200.00 CAD
Jan 1, 2024
1.58 M CAD
Jan 1, 2025
411,000.00 CAD
The Telescope Innovations Receivables history
YEARReceivablesYoY
411,000.00CAD-74.03%
1.58 MCAD+234.45%
473,200.00CAD-34.20%
719,100.00CAD+1,028.89%
63,700.00CAD—
0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telescope Innovations Stock analysis

What does Telescope Innovations do? Telescope Innovations Corp develops and manufactures chemical technologies for pharmaceuticals and chemical industries, focusing on scalable manufacturing processes and tools. The company builds enabling technologies such as flexible robotic platforms and AI software to enhance experimental throughput, efficiency, and data quality. Its core technology supports the discovery of novel therapeutic molecules, while its DILC platform provides quantitative, online reaction monitoring through direct sampling and analysis of chemical reactions. DILC integrates with industry-standard CDS platforms including Agilent OpenLab, Agilent ChemStation, Waters Empower 3, and Shimadzu LabSolutions for unattended sample capture, quenching, dilution, and analysis. The firm sells its DILC platform and related analytical and automation technologies to pharmaceutical and chemical industry clients. These clients include companies requiring advanced reaction monitoring and data analysis capabilities for drug development and chemical manufacturing. The DILC ecosystem targets users needing direct integration with existing CDS systems like Agilent, Waters, and Shimadzu platforms, enabling seamless adoption without extensive reconfiguration. Telescope Innovations Corp generates revenue through the sale of hardware and software components of the DILC platform, as well as associated analytical and automation technologies. The company's products are designed for pharmaceutical and chemical industry segments seeking to improve efficiency and data quality in experimental processes. Clients purchase these solutions to streamline reaction monitoring and analysis, leveraging existing infrastructure with minimal disruption. Telescope Innovations is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telescope Innovations stock

Accounts Receivable of Telescope Innovations is 411,000.00 CAD in 2025.

Accounts Receivable of Telescope Innovations changed from 1.58 M CAD to 411,000.00 CAD, representing a -74.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Telescope Innovations since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Telescope Innovations historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telescope Innovations

All Key Metrics — Telescope Innovations